Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00SWQ
|
|||
| Former ID |
DNCL002891
|
|||
| Drug Name |
Mitoglitazone
|
|||
| Synonyms |
MSDC-0160; Mitoglitazone (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1], [2] | |
| Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [3] | ||
| Company |
Metabolic Solutions Development
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H18N2O4S
|
|||
| Canonical SMILES |
CCC1=CN=C(C=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
|
|||
| InChI |
1S/C19H18N2O4S/c1-2-12-5-8-15(20-10-12)16(22)11-25-14-6-3-13(4-7-14)9-17-18(23)21-19(24)26-17/h3-8,10,17H,2,9,11H2,1H3,(H,21,23,24)
|
|||
| InChIKey |
IRNJSRAGRIZIHD-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 146062-49-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:94409
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | ClinicalTrials.gov (NCT01103414) Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of Mitoglitazone in Type 2 Diabetic Patients. U.S. National Institutes of Health. | |||
| REF 4 | An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. Curr Alzheimer Res. 2014;11(6):564-73. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.